Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Proteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3

GlobeNewswire October 28, 2015

Proteon Therapeutics Appoints Tony Kingsley to Its Board of Directors

GlobeNewswire October 19, 2015

Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015

GlobeNewswire October 12, 2015

Proteon Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire September 2, 2015

Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory Affairs

GlobeNewswire September 1, 2015

Proteon Therapeutics Announces Second Quarter 2015 Financial Results

GlobeNewswire August 13, 2015

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

GlobeNewswire August 13, 2015

Proteon Therapeutics Initiates Second Phase 3 Clinical Study of Investigational Drug Vonapanitase

GlobeNewswire August 12, 2015

Proteon Therapeutics Appoints Scott Canute to Its Board of Directors

GlobeNewswire July 22, 2015

Proteon Therapeutics Announces Addition to Russell 2000 Index

GlobeNewswire June 29, 2015

Proteon Therapeutics to Present at the JMP Securities Life Science Conference June 24th

GlobeNewswire June 17, 2015

Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing

GlobeNewswire June 2, 2015

Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual Congress

GlobeNewswire May 22, 2015

Proteon Therapeutics Announces First Quarter 2015 Financial Results

GlobeNewswire May 13, 2015

Proteon Therapeutics to Present at Two International Vascular Access Conferences

GlobeNewswire April 13, 2015

Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis

GlobeNewswire March 26, 2015

Proteon Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results

GlobeNewswire March 20, 2015

Proteon Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference on March 4th

GlobeNewswire February 26, 2015

Proteon Therapeutics, Inc. (Nasdaq: PRTO) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire February 6, 2015

Proteon Therapeutics to Ring the Nasdaq Stock Market Opening Bell on February 9th

GlobeNewswire February 6, 2015